{"id":"duloxetine-vortioxetine","safety":{"boxedWarning":"Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults taking antidepressants","commonSideEffects":["nausea","dry mouth","dizziness","fatigue","constipation","insomnia"],"contraindications":["concurrent use with MAOIs","uncontrolled narrow-angle glaucoma"]},"_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Serotonin and norepinephrine transporters, 5-HT receptors","explanation":"Duloxetine blocks reuptake of serotonin and norepinephrine, increasing their availability in synapses. Vortioxetine combines serotonin transporter inhibition with agonist and antagonist activity at multiple serotonin receptor subtypes (5-HT1A, 5-HT1B, 5-HT3, 5-HT7). The combination may provide enhanced antidepressant effects through complementary mechanisms.","oneSentence":"Duloxetine inhibits serotonin and norepinephrine reuptake; vortioxetine modulates serotonin through receptor activity and reuptake inhibition."},"_scrapedAt":"2026-03-28T02:35:49.418Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122891,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"Escitalopram","brand":"Lexapro","company":"Allergan","rationale":"SSRI widely used as first-line treatment for major depressive disorder"},{"name":"Desvenlafaxine","brand":"Pristiq","company":"Pfizer","rationale":"SNRI antidepressant with similar mechanism to duloxetine component"},{"name":"Vilazodone","brand":"Viibryd","company":"Allergan","rationale":"Multimodal antidepressant with partial 5-HT1A agonist activity"}],"description":"Duloxetine and vortioxetine are antidepressants being studied in combination by Johns Hopkins Bloomberg School of Public Health in a Phase 2 trial. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI), while vortioxetine is a multimodal antidepressant with serotonin modulator activity.","indications":{"approved":[{"status":"investigational","condition":"Major Depressive Disorder","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT05267873","phase":"","title":"Combining Data Sources to Identify Effect Moderation for Personalized Mental Health","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2015-01-01","conditions":"Depressive Disorder, Major","enrollment":9586},{"nctId":"NCT04446039","phase":"","title":"Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-07-04","conditions":"Major Depression","enrollment":370212},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT06025474","phase":"PHASE3","title":"Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2023-01-01","conditions":"Burning Mouth Syndrome","enrollment":203},{"nctId":"NCT05952713","phase":"","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","status":"COMPLETED","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2022-10-01","conditions":"Major Depressive Disorder","enrollment":73336},{"nctId":"NCT01564862","phase":"PHASE2","title":"Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-04","conditions":"Depressive Disorder, Major","enrollment":602},{"nctId":"NCT00635219","phase":"PHASE3","title":"Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2008-02","conditions":"Major Depressive Disorder","enrollment":766},{"nctId":"NCT01140906","phase":"PHASE3","title":"Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2010-05","conditions":"Major Depressive Disorder","enrollment":607},{"nctId":"NCT00811252","phase":"PHASE3","title":"Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2009-01","conditions":"Major Depressive Disorder","enrollment":453},{"nctId":"NCT00672620","phase":"PHASE3","title":"Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-04","conditions":"Major Depressive Disorder","enrollment":611},{"nctId":"NCT01153009","phase":"PHASE3","title":"Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-06","conditions":"Depressive Disorder, Major","enrollment":614},{"nctId":"NCT00730691","phase":"PHASE3","title":"Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-06","conditions":"Generalized Anxiety Disorder","enrollment":781}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":115,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Duloxetine, Vortioxetine","genericName":"Duloxetine, Vortioxetine","companyName":"Johns Hopkins Bloomberg School of Public Health","companyId":"johns-hopkins-bloomberg-school-of-public-health","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}